How to improve access to therapy ?

The situation in Spain

# R Esteban

Liver Unit
Hospital Universitario Valle Hebron. Barcelona, Spain

Hepatitis C in Spain

Situation at the start of the Plan

Anti HCV prevalence	**1,7%** **(0,4 – 2,6)**
Adults with antiHCV positive	688.000 (159.000 – 1.049.000)
HCV RNA positive in anti-HCV +ve	68,6%
Prevalence of HCV RNA +ve	1,2% (0,3 – 1,8)
Number of Viremic Subjects	472.000 (109.000 – 719.000)
HCV Genotype distribution	1a: 25,5% 1b: 43,8% 2: 3,1% 3: 19,6% 4: 8%

Spain Hepatitis C Action Plan

Aim of the Plan:

To Reduce HCV morbidity/mortality in the Spanish population

Objective

Make Prevention/Diagnosis/Treatment
and Follow up of the patients

Intervention

Euros 1000 million additional investment 2015-17

Phase 1

2015-2017

. Criteria for HCV Treatment

➤ All patients with Chronic Hepatitis C should be considered candidates for antiviral treatment.

➤ In view of the **scale of the infection in Spain**, treatment must be **prioritised for patients with**

- **significant liver fibrosis (F2 to F4)**

- **clinically relevant extrahepatic manifestation**

- Patients on the **waiting list for transplant** (liver or non-liver)

- **Solid organ transplanted patients**

- Patients with a high risk of infection transmission

- Women at fertile age who wish to get pregnant.

Criteria for HCV treatment in the National Health System

➢ In patients with fibrosis **F0-F1**, the treatment can be deferred and its indication can be regarded individually

➢ These patients must be closely monitored and it must be observed whether there are relevant changes in their evolution or in the progression of their disease.

PATIENTS TREATED IN THE NATIONAL STRATEGIC PLAN 2015

TOTAL
- 24491
- 27645

VIEKIRAX/EXVIERA
- 6292
- 6292
- 3154

HARVONI
- 11450
- 11450
- 2475

SOVALDI/OLYSIO/DAKLINZA
- 5932
- 8407
- 679

OLYSIO+INTERFERON
- 817
- 1496

■ PACIENTES TRATADOS 1 ENERO - 30 DE SEPTIEMBRE
■ PACIENTES TRATADOS 1 ABRIL-30 DE SEPTIEMBRE
■ PACIENTES TRATADOS ENERO -31 DE MARZO

Summary

Prevalence of HCV in Spain between 0,4 – 2,6 %

National Plan Against hepatitis HCV from March 2015

Funding 1 billion Euros 2015-2017

Access to DAAs: F2 to F4/ Extrahepatic manifestations and/ or

 high risk of infectivity with F0-F1

27,643 Patients treated March to September 2015

 Future: Update epidemiology, National Registry of Patients,

 Increase diagnosis and treatment